Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranitidine duty suspension

Executive Summary

International Trade Commission study on domestic economic impact of duty suspension requested for Senate Finance Committee by Jan. 18. Duty suspension legislation (HR 3130) for the active ingredient in Glaxo's Zantac was stopped in the 101st Congress by an objection from SmithKline Beecham. Study has been requested to assess whether duty suspension for the ingredient would unfairly affect Tagamet ("The Pink Sheet" Oct. 1, T&G-4).



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts